Advertisement

Comparison of Platelet Reactivity and Clopidogrel Response in Patients ≤75 Years Versus >75 Years Undergoing Percutaneous Coronary Intervention for Non–ST-Segment Elevation Acute Coronary Syndrome

      Specific data about the clopidogrel response in elderly patients are lacking. The present study was performed to compare the platelet reactivity and clopidogrel response between patients aged >75 years and <75 years undergoing percutaneous coronary intervention for non–ST-segment elevation acute coronary syndrome. A total of 689 patients were enrolled, including 162 patients aged >75 years and 527 younger patients. All patients received a loading dose of 600 mg clopidogrel followed by 150 mg/day. Post-treatment platelet reactivity was assessed by adenosine diphosphate 10 μmol/L-induced platelet aggregation and the specific pharmacologic response to clopidogrel by the platelet reactivity index vasoactive stimulated phosphoprotein. High post-treatment platelet reactivity was defined as adenosine diphosphate 10 μmol/L-induced platelet aggregation >70%. Clinical events were recorded during 1 month of follow-up. The patients >75 years old had a greater rate of both ischemic and bleeding complications (p = 0.04 and p = 0.03, respectively). The post-treatment platelet reactivity in response to both the loading and the maintenance clopidogrel dose was greater in patients >75 years old than in the younger patients: 50 ± 17% versus 45 ± 17% (p = 0.002) and 57 ± 15% versus 53 ± 16% (p = 0.0005), respectively. The rate of high post-treatment platelet reactivity was significantly greater in patients aged >75 years after 600 mg and 150 mg clopidogrel: 14% versus 9% (p = 0.04) and 23% versus 15% (p = 0.02), respectively. In contrast, the pharmacologic response to clopidogrel was not impaired in patients >75 years after loading and maintenance doses: 43 ± 21% versus 46 ± 21% (p = 0.17) and 38 ± 18% versus 39 ± 18% (p = 0.55), respectively. In conclusion, patients aged >75 years have an impaired prognosis after acute coronary syndrome. They display greater post-treatment platelet reactivity. However, this greater platelet reactivity does not seem to be related to an impaired specific response to clopidogrel.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bertrand M.E.
        • Rupprecht H.J.
        • Urban P.
        • Gershlick A.H.
        • CLASSICS Investigators
        Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS).
        Circulation. 2000; 102: 624-629
        • Yusuf S.
        • Zhao F.
        • Mehta S.R.
        • Chrolavicius S.
        • Tognoni G.
        • Fox K.K.
        • Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators
        Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
        N Engl J Med. 2001; 345: 494-502
        • Mehta S.R.
        • Yusuf S.
        • Peters R.J.
        • Bertrand M.E.
        • Lewis B.S.
        • Natarajan M.K.
        • Malmberg K.
        • Rupprecht H.
        • Zhao F.
        • Chrolavicius S.
        • Copland I.
        • Fox K.A.
        • Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators
        Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
        Lancet. 2001; 358: 527-533
        • Angiolillo D.J.
        • Fernandez-Ortiz A.
        • Bernardo E.
        • Alfonso F.
        • Macaya C.
        • Bass T.A.
        • Costa M.A.
        Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives.
        J Am Coll Cardiol. 2007; 49: 1505-1516
        • Matetzky S.
        • Shenkman B.
        • Guetta V.
        • Schechter M.
        • Bienart R.
        • Goldenberg I.
        • Novikov I.
        • Pres H.
        • Savion N.
        • Varon D.
        • Hod H.
        Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
        Circulation. 2004; 109: 3171-3175
        • Cuisset T.
        • Frere C.
        • Quilici J.
        • Barbou F.
        • Morange P.E.
        • Hovasse T.
        • Bonnet J.L.
        • Alessi M.C.
        High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome.
        J Thromb Haemost. 2006; 4: 542-549
        • Geisler T.
        • Langer H.
        • Wydymus M.
        • Göhring K.
        • Zürn C.
        • Bigalke B.
        • Stellos K.
        • May A.E.
        • Gawaz M.
        Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation.
        Eur Heart J. 2006; 27: 2420-2425
        • Hochholzer W.
        • Trenk D.
        • Bestehorn H.P.
        • Fischer B.
        • Valina C.M.
        • Ferenc M.
        • Gick M.
        • Caputo A.
        • Büttner H.J.
        • Neumann F.J.
        Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement.
        J Am Coll Cardiol. 2006; 48: 1742-1750
        • Buonamici P.
        • Marcucci R.
        • Migliorini A.
        • Gensini G.F.
        • Santini A.
        • Paniccia R.
        • Moschi G.
        • Gori A.M.
        • Abbate R.
        • Antoniucci D.
        Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis.
        J Am Coll Cardiol. 2007; 49: 2312-2317
        • Cuisset T.
        • Cayla G.
        • Frere C.
        • Quilici J.
        • Poyet R.
        • Gaborit B.
        • Bali L.
        • Morange P.E.
        • Alessi M.C.
        • Bonnet J.L.
        Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome: shifting from antiplatelet resistance to bleeding risk assessment?.
        EuroIntervention. 2009; 5: 325-329
        • Sibbing D.
        • Schulz S.
        • Braun S.
        • Morath T.
        • Stegherr J.
        • Mehilli J.
        • Schömig A.
        • von Beckerath N.
        • Kastrati A.
        Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement.
        J Thromb Haemost. 2010; 8: 250-256
        • Alexander K.P.
        • Newby L.K.
        • Cannon C.P.
        • Armstrong P.W.
        • Gibler W.B.
        • Rich M.W.
        • Van de Werf F.
        • White H.D.
        • Weaver W.D.
        • Naylor M.D.
        • Gore J.M.
        • Krumholz H.M.
        • Ohman E.M.
        • American Heart Association Council on Clinical Cardiology
        • Society of Geriatric Cardiology
        • Society of Geriatric Cardiology
        Acute coronary care in the elderly, part I: Non–ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology.
        Circulation. 2007; 115: 2549-2569
        • Alexander K.P.
        • Newby L.K.
        • Armstrong P.W.
        • Cannon C.P.
        • Gibler W.B.
        • Rich M.W.
        • Van de Werf F.
        • White H.D.
        • Weaver W.D.
        • Naylor M.D.
        • Gore J.M.
        • Krumholz H.M.
        • Ohman E.M.
        • American Heart Association Council on Clinical Cardiology
        • Society of Geriatric Cardiology
        • Society of Geriatric Cardiology
        Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology.
        Circulation. 2007; 115: 2570-2589
        • Avezum A.
        • Makdisse M.
        • Spencer F.
        • Gore J.M.
        • Fox K.A.
        • Montalescot G.
        • Eagle K.A.
        • White K.
        • Mehta R.H.
        • Knobel E.
        • Collet J.P.
        • GRACE Investigators
        Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE).
        Am Heart J. 2005; 149: 67-73
        • Hochholzer W.
        • Trenk D.
        • Fromm M.F.
        • Valina C.M.
        • Stratz C.
        • Bestehorn H.P.
        • Büttner H.J.
        • Neumann F.J.
        Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement.
        J Am Coll Cardiol. 2010; 55: 2427-2434
        • Gremmel T.
        • Steiner S.
        • Seidinger D.
        • Koppensteiner R.
        • Panzer S.
        • Kopp C.W.
        Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel.
        J Thromb Haemost. 2010; 8: 37-42
        • Mehta S.R.
        • Bassand J.P.
        • Chrolavicius S.
        • Diaz R.
        • Eikelboom J.W.
        • Fox K.A.
        • Granger C.B.
        • Jolly S.
        • Joyner C.D.
        • Rupprecht H.J.
        • Widimsky P.
        • Afzal R.
        • Pogue J.
        • Yusuf S.
        • CURRENT-OASIS. 7 Investigators
        Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
        N Engl J Med. 2010; 363: 930-942
        • Schwarz U.R.
        • Geiger J.
        • Walter U.
        • Eigenthaler M.
        Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets—definition and detection of ticlopidine/clopidogrel effects.
        Thromb Haemost. 1999; 82: 1145-1152
        • Bonello L.
        • Tantry U.S.
        • Marcucci R.
        • Blindt R.
        • Angiolillo D.J.
        • Becker R.
        • Bhatt D.L.
        • Cattaneo M.
        • Collet J.P.
        • Cuisset T.
        • Gachet C.
        • Montalescot G.
        • Jennings L.K.
        • Kereiakes D.
        • Sibbing D.
        • Trenk D.
        • Van Werkum J.W.
        • Paganelli F.
        • Price M.J.
        • Waksman R.
        • Gurbel P.A.
        • Working Group on High On-Treatment Platelet Reactivity
        Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.
        J Am Coll Cardiol. 2010; 56: 919-933
        • Laskey W.K.
        • Yancy C.W.
        • Maisel W.H.
        Thrombosis in coronary drug-eluting stents: report from the meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health, December 7–8, 2006.
        Circulation. 2007; 115: 2352-2357
        • Cuisset T.
        • Frere C.
        • Poyet R.
        • Quilici J.
        • Gaborit B.
        • Bali L.
        • Brissy O.
        • Lambert M.
        • Morange P.E.
        • Alessi M.C.
        • Bonnet J.L.
        Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting.
        Arch Cardiovasc Dis. 2010; 103: 39-45
        • Angiolillo D.J.
        • Fernández-Ortiz A.
        • Bernardo E.
        • Barrera Ramírez C.
        • Sabaté M.
        • Fernandez C.
        • Hernández-Antolín R.
        • Escaned J.
        • Alfonso F.
        • Macaya C.
        Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?.
        J Invasive Cardiol. 2004; 16: 169-174
        • Wiviott S.D.
        • Braunwald E.
        • McCabe C.H.
        • Montalescot G.
        • Ruzyllo W.
        • Gottlieb S.
        • Neumann F.J.
        • Ardissino D.
        • De Servi S.
        • Murphy S.A.
        • Riesmeyer J.
        • Weerakkody G.
        • Gibson C.M.
        • Antman E.M.
        • TRITON-TIMI 38 Investigators
        Prasugrel versus clopidogrel in patients with acute coronary syndromes.
        N Engl J Med. 2007; 357: 2001-2015
        • Wallentin L.
        • Becker R.C.
        • Budaj A.
        • Cannon C.P.
        • Emanuelsson H.
        • Held C.
        • Horrow J.
        • Husted S.
        • James S.
        • Katus H.
        • Mahaffey K.W.
        • Scirica B.M.
        • Skene A.
        • Steg P.G.
        • Storey R.F.
        • Harrington R.A.
        • Freij A.
        • Thorsén M.
        • PLATO Investigators
        Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
        N Engl J Med. 2009; 361: 1045-1057
        • Price M.J.
        • Berger P.B.
        • Teirstein P.S.
        • Tanguay J.F.
        • Angiolillo D.J.
        • Spriggs D.
        • Puri S.
        • Robbins M.
        • Garratt K.N.
        • Bertrand O.F.
        • Stillablower M.E.
        • Aragon J.R.
        • Kandzari D.E.
        • Stinis C.T.
        • Lee M.S.
        • Manoukian S.V.
        • Cannon C.P.
        • Schork N.J.
        • Topol E.J.
        • GRAVITAS Investigators
        Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
        JAMA. 2011; 305: 1097-1105
        • Collet J.P.
        • Cayla G.
        • Cuisset T.
        • Elhadad S.
        • Rangé G.
        • Vicaut E.
        • Montalescot G.
        Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel after DES implantation, and (2) treatment interruption versus continuation, 1 year after stenting (ARCTIC) study.
        Am Heart J. 2011; 161: 5-12